FOR IMMEDIATE RELEASE
July 29, 2019

GraftWorx Initiates Remote Monitoring Service Evaluation with Academic Health Science Network and a National Health Service Nephrology Unit in North East England

ENABLING PRECISION MEDICINE WITH REAL-TIME DATA

South San Francisco, CA — July 29, 2019 —
GraftWorx, Inc has commenced a service evaluation in collaboration with the Academic Health Science Network (AHSN) and a National Health Service (NHS) Hospital Foundation Trust based in the North East of England.  After evaluating early data against standard measures, the teams hope to undertake formal studies that will utilize the Graftworx remote monitoring solution to assess patients on dialysis and those with heart failure.  Cumulatively these studies will gather both clinical and outcome data on 150 patients for up to three years, over the course of their existing treatment in-clinic as well as outside the clinic.

“Our mission at GraftWorx is to improve the care of patients living with chronic conditions, such as dialysis and heart failure, by enabling more effective and personalized fluid management, for both populations, as well vascular access management for those on dialysis. We are excited to partner with the AHSN at the NHS England on a series of studies that will further hone our remote monitoring solution, articulate the impact on the clinic and patient outcomes, and progress our pipeline of pursuing multiple clinical use cases with our technology.” David Kuraguntla, CEO GraftWorx.

“We look forward to partnering with GraftWorx to drive the real world innovation of viable, clinical-grade remote monitoring solutions for key patient populations such as those on dialysis and those diagnosed with heart failure.” said Professor Oliver James, Medical Director of AHSN North East and North Cumbria.

Dr Jonathan Murray, Consultant Nephrologist at South Tees Hospitals NHS Foundation Trust in Middlesbrough, said “The range of assessments that we are planning with GraftWorx is based upon the premise that remotely and continuously capturing early clinical signals will enable our clinical teams to more promptly identify potential problems.  Ultimately we are keen to evaluate if digital health enabled data will improve efficiency and effectiveness of patient care and thereby optimize our care pathways.”

For more information on GraftWorx:

David Kuraguntla, GraftWorx
david.kuraguntla@graftworx.com